Clinical-Trail-Methode

Trial discontinuation: lessons for future trial design?

Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude

• Abstrakt

Rückblick: Ergebnisse klinischer Studien

Clinical evidence of the role of edoxaban in anticoagulation

Elena Fortuny ,Jose Zamorano

• Abstrakt

Clinical-Trail-Methode

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease

Donald R VanDevanter,Michael W Konstan

• Abstrakt

Clinical-Trail-Methode

New considerations in the design of clinical trials for traumatic brain injury

Bob Roozenbeek, Hester F Lingsma Andrew I R Maas

• Abstrakt

Forschungsupdate

Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies

Marinus W Lobbezoo, A Hilary Calvert, Elizabeth A Eisenhauer,Giuseppe Giaccone

• Abstrakt

Sonderbericht

Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies

Lucy Lee

• Abstrakt

Rückblick: Ergebnisse klinischer Studien

Telaprevir in the treatment of hepatitis C infection: evidence from the ADVANCE, ILLUMINATE and REALIZE studies

Joseph Ahn, Steven Flamm

• Abstrakt

Rückblick: Ergebnisse klinischer Studien

Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer

Carole Gourmelon, Jean Sebastien Frenel,Mario Campone

• Abstrakt

Klinische Trail-Perspektive

Research involving pregnant women: trials and tribulations

Francoise Baylis, Scott A. Halperin

• Abstrakt

Therapeutische Perspektive

Emergence of Neisseria meningitidis W-135 in the context of other rare serogroups

Luiz Jacintho da Silva, Lisa DeTora, Claudius Malerczyk & Ziad A Memish

• Abstrakt